Blueprint Medicines Corp reports results for the quarter ended in September - Earnings Summary

Blueprint Medicines

01/11/2022 13:33

* Blueprint Medicines Corp  BPMC.OQ  reported a quarterly
adjusted
loss of $2.23​​ per share for the quarter ended in September.
The mean expectation of seventeen analysts for the quarter was
for a loss of $2.49 per share.
    * Revenue rose 172.8% to $65.98 million from a year ago;
analysts
expected $43.42 million. 
    * Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of $2.23​.
    * The mean earnings estimate of analysts had fallen by
about 3.8%
in the last three months.​ 
    * In the last 30 days two analysts negatively revised
earnings
estimates 
    * Blueprint Medicines Corp shares had fallen by 21.3% this
quarter and lost 51.6% so far this year.
    * The company reported a quarterly loss of $133.16 million.
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $90.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
1 at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -2.49          -2.23          Beat
 Jun. 30 2022      -2.23          -2.68          Missed
 Mar. 31 2022      -1.86          -1.79          Beat
 Dec. 31 2021      -1.65          -5.40          Missed